PHOENIX, AZ, Apr 28, 2026 – Pete Pharma is expanding North American access to automated solid-dose manufacturing through Fagron’s pharmacy channel. The agreement appoints Fagron as a reseller of Pete Pharma’s 3D pharmaceutical printing systems for 503A and 503B pharmacies in the United States and Canada.
The partnership combines the FABRx and Pete Pharma 3D pharmaceutical printing platform with Fagron’s commercial network in the compounding industry. The system includes M3DIMAKER hardware, software infrastructure, and drug delivery systems for automated solid dosage form manufacturing.
The technology supports pharmacy production of immediate-release tablets, extended-release formulations, oral films, troches, water-dissolvable tablets, chewables, and suppositories. The agreement places these dosage formats within a structured commercial framework for compounding pharmacies.
“This partnership represents a significant step in scaling access to pharmaceutical 3D printing technology,” said Marc Joiner, co-founder of Pete Pharma. “Fagron has built a strong global presence within the compounding industry. By aligning our platform with their commercial infrastructure, we are creating a clear pathway for pharmacies to adopt advanced manufacturing capabilities and expand their product offerings.”
“This collaboration allows us to bring next-generation pharmaceutical manufacturing solutions to our customers in a structured and scalable way,” said Andrew Allan, vice president, sales at Fagron. “Pete Pharma’s platform represents a meaningful advancement in how compounded medications can be developed and delivered. We are excited to support the expansion of this technology across our network,” said Amy Jones, Business Leader at Fagron.
Both the companies plan to expand the use of 3D pharmaceutical printing in pharmacy-based manufacturing workflows. The partnership links automated production systems with Fagron’s reseller channel for solid-dose manufacturing in North America.
Source: Pete Pharma
About Pete Pharma
Pete Pharma is a U.S.-based pharmaceutical manufacturing company that develops drug delivery systems and production technologies. It focuses on 3D pharmaceutical printing, programmable dosage forms, and automated solid-dose manufacturing. The company produces immediate-release and extended-release forms, oral films, troches, chewables, and suppositories. Pete Pharma serves pharmacies, group purchasing organizations, and pharmaceutical partners. It also works with partners through licensing and collaboration models to deploy formulations and manufacturing processes. The company is headquartered in Phoenix, AZ. Its technology uses precision dispensing, integrated mold systems, and programmable pharmaceutical bases to enable flexible dosing from concentrated formulations. The approach supports automated production and reduces manual compounding steps.
About Fagron
Fagron is a multinational pharmaceutical company that supplies products and services for pharmaceutical compounding. It develops and distributes raw materials, compounded medications, and related services used to prepare customized medicines. The company serves hospitals, pharmacies, clinics, prescribers, and healthcare institutions. Fagron was founded in 1990 and is headquartered in Rotterdam, Netherlands. Its operations cover sourcing, formulation, production, and distribution across the compounding supply chain. The company operates in more than 30 countries across Europe, the Americas, and Asia. Its products support cases where standard medicines are not suitable, including alternative dosage forms and strengths. Fagron has served about 150,000 customers in more than 55 countries. The company employs more than 3,000 people worldwide.